Ethics Group Approves Lexaria Bioscience Corp (OTC
Post# of 4861
(Total Views: 191)
Posted On: 10/05/2020 5:50:01 PM
Ethics Group Approves Lexaria Bioscience Corp (OTCMKTS:LXRP) To Carry Out The Study Using CBD To Assess Reduction In Blood Pressure
David Fisher October 2, 2020
European University Research Hospital’s Ethics Board approved Lexaria Bioscience Corp (OTCMKTS:LXRP) to carry out an exploratory study involving CBD and with or without DehydraTECH to assess the reduction in blood pressure. It will conduct the study in patients with mild pre-hypertension using CBD formulated with DehydraTech.
24 participants in the study
The cross-over, double-blinded, placebo-controlled pilot study will be conducted in 24 volunteers (12 females and 12 males aged 45 and 70). They will be administered with 300 mg of cannabidiol either with or without DehydraTech in oral capsule form. The primary objective of the study is to measure heart rate and blood pressure automatically. In the secondary endpoint, the company targets plasma concentrations of cannabidiol and assesses the key inflammatory markers related to cardiovascular disease.
The new study will complement the previous clinical study of Lexaria conducted in 2018. 90 mg of TurboCBD in the Oral capsule form of Lexaria is administered in 2018 and found the evidence of improved blood flow to the brain and a reduction in blood pressure.
According to the observations of a study conducted in 2018, CBD formulation helped to achieve a 5% reduction in MAP (mean arterial blood pressure). The company hopes to preserve the previously demonstrated results and improve the dosage compared to the 2018 study, and assess the formula.
Chairman of Lexaria, Chris Bunka, said the company plans to explore partnering opportunities in the pharmaceutical industry using its DehydraTech platform to achieve success in this study. The demand for antihypertensive products is more than $22 billion. Lexaria expects to reveal study results in November 2020.
https://drpgazette.com/2020/10/02/ethics-grou...-pressure/?
David Fisher October 2, 2020
European University Research Hospital’s Ethics Board approved Lexaria Bioscience Corp (OTCMKTS:LXRP) to carry out an exploratory study involving CBD and with or without DehydraTECH to assess the reduction in blood pressure. It will conduct the study in patients with mild pre-hypertension using CBD formulated with DehydraTech.
24 participants in the study
The cross-over, double-blinded, placebo-controlled pilot study will be conducted in 24 volunteers (12 females and 12 males aged 45 and 70). They will be administered with 300 mg of cannabidiol either with or without DehydraTech in oral capsule form. The primary objective of the study is to measure heart rate and blood pressure automatically. In the secondary endpoint, the company targets plasma concentrations of cannabidiol and assesses the key inflammatory markers related to cardiovascular disease.
The new study will complement the previous clinical study of Lexaria conducted in 2018. 90 mg of TurboCBD in the Oral capsule form of Lexaria is administered in 2018 and found the evidence of improved blood flow to the brain and a reduction in blood pressure.
According to the observations of a study conducted in 2018, CBD formulation helped to achieve a 5% reduction in MAP (mean arterial blood pressure). The company hopes to preserve the previously demonstrated results and improve the dosage compared to the 2018 study, and assess the formula.
Chairman of Lexaria, Chris Bunka, said the company plans to explore partnering opportunities in the pharmaceutical industry using its DehydraTech platform to achieve success in this study. The demand for antihypertensive products is more than $22 billion. Lexaria expects to reveal study results in November 2020.
https://drpgazette.com/2020/10/02/ethics-grou...-pressure/?
(2)
(0)